JAK2 and essential thrombocythemia: Among patients with ET, 42 patients (63.7%) had JAK2 V617F mutation, 15 patients (22.7%) had CALR mutation, and 9 patients (13.6%) were negative for both JAK2 V617F and CALR mutations (in our hospital, MPL cannot be assessed).